Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
General Outlook
In simple terms, Pfizer Inc. has 5646.41 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 0.694% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.349%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.275%. This tells us they're good at keeping money after all costs.
Return on Investments
The company's asset efficiency, represented by a robust 0.110% return, is a testament to Pfizer Inc.'s adeptness in optimizing resource deployment. Pfizer Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.223%. Furthermore, the proficiency of Pfizer Inc. in capital utilization is underscored by a remarkable 0.171% return on capital employed.
Stock Prices
Pfizer Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $28, while its low point bottomed out at $26.3. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Pfizer Inc.'s stock market.
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”